Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an update.
Aroa Biosurgery Limited reported a 14% increase in total revenue for the first half of FY26, reaching NZ$44.9 million, with significant growth in its Myriad product line. The company achieved a normalized EBITDA profit of NZ$1.8 million, a significant improvement from a loss in the previous year, and ended the period with a positive net cash flow. Aroa also received relief from quarterly reporting requirements by the ASX, indicating a stable financial position and operational efficiency. The company reaffirmed its FY26 guidance, projecting continued revenue growth and improved EBITDA, signaling a positive outlook for stakeholders.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited is a company specializing in soft tissue regeneration. It is known for its products like Myriad and OviTex, which are used in medical procedures to aid in tissue repair and healing. The company focuses on providing innovative solutions in the biosurgery industry.
Average Trading Volume: 321,514
Technical Sentiment Signal: Buy
Current Market Cap: A$231.2M
See more data about ARX stock on TipRanks’ Stock Analysis page.